HepaRegeniX

Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). A first compound has recently started clinical development.
MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.

Press releases

Press
21. January 2020
HepaRegeniX GmbH secures Series B Financing in excess of €11 Mio. to advance first drug candidate to the clinic
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models. HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases today announced the closing of its Series B financing round in excess of €11 Mio. with contribution from all its existing investors namely Boehringer Ingelheim Venture Fund GmbH (BIVF), Novo Holdings A/S, the High-Tech Gründerfonds,
 
Press
5. January 2017
HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases
HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion. HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Ger
 

Info & Contact

Dr. Michael Lutz, Managing Director
Phone:
49 (0)7071 7912810

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
D-72072 Tübingen

In portfolio

14. Nov 2016

HTGF Manager

 
Dr. Frank Hensel, Principal / Authorized signatory